Milestone Event Milestone Payment. [***] [***]
Milestone Event Milestone Payment. 1. First [**] filing with the [**] for a Class of [**]Engineered T-Cell Product that differs from the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 and Milestone Event B.1 above on the basis of clause (b) of Section 1.15 but is the same Class as the Class of [**] Engineered T-Cell Product that was the subject of Milestone Event A.4 above on the basis of Gene Target [**]
Milestone Event Milestone Payment. 1. The first time in which worldwide, aggregate Net Sales in a calendar year of [**] Engineered T-Cell Products exceeds $[**] [**]
Milestone Event Milestone Payment. 6 First time Annual Net Sales of all Products exceed $[***] $[***]
Milestone Event Milestone Payment. (i) First dosing of a subject in a Phase I Study of a Licensed Product $10,000,000 [**] [**] [**] [**] [**] [**] [**] [**]
Milestone Event Milestone Payment. Initial Milestone Events
Milestone Event Milestone Payment. Initiation of first GLP Toxicology Study of a Product under the Initial Program [*]
Milestone Event Milestone Payment. First Commercial Sale of a Product under the Initial Program [*] Worldwide Net Sales of Products under the Initial Program exceed [*] in a calendar year [*] Worldwide Net Sales of Products under the Initial Program exceed [*] in a calendar year [*] Worldwide Net Sales of Products under the Initial Program exceed [*] in a calendar year [*]
Milestone Event Milestone Payment. Initiation of first Phase 2 Clinical Trial of a Product under the applicable Post-Effective Date Program [*] Initiation of first Phase 3 Clinical Trial of a Product under the applicable Post-Effective Date Program [*]
